FOSTER CITY (dpa-AFX) - The U.S. Food and Drug Administration approved Gilead Sciences Inc.'s (GILD) Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients living with
On December 9, 2022, Arcellx, Inc. entered into a Collaboration and License Agreement with Kite Pharma, Inc., a Gilead Company , pursuant to which Arcellx and Kite will collaborate on the development. | December 10, 2022
FOSTER CITY (dpa-AFX) - ImmunoGen, Inc. (IMGN) announced a clinical collaboration with Gilead Sciences, Inc. (GILD) to evaluate the safety and anti-leukemia activity of pivekimab sunirine in combination
FOSTER CITY (dpa-AFX) - Daiichi Sankyo Co., Ltd. (DSKYF.PK) will transfer yescarta marketing authorization in Japan to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences Inc. (GILD)
The U.S. Supreme Court on
Monday rebuffed a bid by Bristol Myers Squibb Co s Juno
Therapeutics Inc to reinstate a $1.2 billion award it won in its
patent fight with Gilead Sciences Inc subsidiary. | November 7, 2022